Natural Killer Cell Recognition and Control of Epithelial Cancers

Marcelo de Souza Fernandez Pereira, PhD,* David R. Carr, MD, MPH,†† Margaret E. Gatti-Mays, MD, MPH,‡‡ Mallery R. Olsen, MD,§|| Bhuvana A. Setty, MD,§|| Kathryn T. Shahwan, MD,‡‡ and Dean A. Lee, MD, PhD*§||

Abstract: Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and unique human studies of each that is supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.

Key Words: Carcinoma, natural killer cells, neuroepithelial cancer

(Cancer J 2022;28: 263–269)

Natural killer (NK) cells are large granular lymphocytes that make up a small proportion of peripheral blood leukocytes but serve an important role in immune recognition of cancers and viral infections. The anticaner role of NK cells has been most studied in hematologic malignancies, particularly in the setting of allogeneic hematopoietic stem cell transplantation, but interest has recently increased in adapting them to the solid tumor setting. The solid tumor setting, however, presents unique challenges for cellular therapies with respect to migration and homing to tumor sites, targeting of tumor cells, and survival in harsh solid tumor microenvironments.

Nonmelanoma Skin Cancers

Natural killer cell dysregulation has been implicated in the pathogenesis of nonmelanoma skin cancers, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC). Basal cell carcinoma is the most common malignancy worldwide, affecting approximately 2 million individuals in the United States each year.1 Basal cell carcinoma has a low risk of metastasis but can be associated with significant tissue destruction in advanced cases; these outcomes are most common in high-risk histologic subtypes such as micronodular, morpheaform, and infiltrative BCC and in tumors with perineural invasion.2 Although surgical treatment with excision or Mohs micrographic surgery is the mainstay of treatment, topical immunomodulation agents such as imiquimod and ingenol mebutate are useful in select cases.3 The activity of NK cells can be suppressed through HLA binding to inhibitory killer-cell immunoglobulin-like receptors (KIRs), and activating KIR haplotypes have been associated with the development of multiple BCCs.3,4 Furthermore, p53 is necessary for NK ligand upregulation, and p53 mutations have been associated with this activating KIR haplotype, as well as BCC pathogenesis.4 Although isolated NK cell–based therapies have not yet been studied in the treatment of BCC, innate NK cells have been implicated in the local immune response that drives the effectiveness of the topical immunomodulation agents ingenol mebutate and imiquimod.4,5 The incidence of CSCC is also rising.6 Although most CSCCs are curable by surgical intervention alone, a subset of tumors harbors high-risk features and is at an increased risk of adverse outcomes including local recurrence, regional and distant metastasis, and disease-specific death.7 The immunogenicity of CSCC has been well established. First, immunosuppression impacts a significantly increased risk of CSCC development, with solid organ transplant recipients having up to 250 times the incidence compared with the general population; the CSCCs seen in this patient population are also more likely to display aggressive behavior, with a significantly higher risk of poor outcomes.10 In addition, immune checkpoint inhibitors such as cemiplimab (anti–programmed cell death 1) have shown great promise in the treatment of advanced tumors, further evidence of the critical role of the immune system in CSCC pathogenesis.11 Impaired NK function in particular has been shown to play a pivotal role in the development and progression of CSCC. Patients with functional NK T cell deficiency have higher rates of CSCC, independent of human papillomavirus infection.12,13 Low levels of NK cells in the peripheral blood of renal transplant recipients have also been shown to be predictive of CSCC development.14 Furthermore, cetuximab, an epidermal growth factor receptor inhibitor that is effective in the treatment of advanced CSCC cases, exerts its effect in part due to NK cell activation.15 Given this collective evidence, it is hypothesized that NK cell activation may be a novel therapeutic target for CSCC.16 Although NK cell therapy for CSCC has not yet been studied in humans, in mouse models, induced NK deficiency resulted in increased CSCC tumor growth, and adoptive transfer of purified NK cells decreased tumor size.17,18

Breast Carcinoma

Breast cancer has historically been considered a cold tumor and evades the immune system through a variety of strategies that decrease NK cell activation.19,20 Evasion tactics used by breast tumors include downregulating the NK cell activating receptor...
NKG2D through increased release of its ligand, major histocompatibility complex (MHC) class I–related MICA molecule from tumors,21 overexpression of self-signals HLA-E and HLA-G that inhibit activation through binding to NKG2A,22 and increased anti-inflammatory cytokines (transforming growth factor β [TGF-β], interleukin 10 [IL-10]) that lead to NK cell dysfunction.23,24 Although NK cells play a role in all 3 main breast cancer subtypes (hormone receptor positive or HER2 positive or triple negative), the impact of NK-targeting approaches has been most commonly evaluated in HER2-positive breast cancer, where NK cell activation promotes antibody-dependent cellular cytotoxicity (ADCC)–induced tumor killing by monoclonal antibodies (such as trastuzumab, pertuzumab, or TDM1). Antibody-dependent cellular cytotoxicity, in turn, results in the release of cytokines and chemokines and the direction of dendritic cells, macrophages, and T cells to the HER2-positive tumor.19,25 Given that HER2-positive breast cancers account for approximately 20% of all breast tumors and the aggressiveness conferred by the expression of the HER2 oncogene,24 there is a strong rationale for evaluating NK cell augmentation of these commonly used HER2-targeting antibodies.25

The KIR functional genotype has been suggested as a predictive biomarker for pathologic complete response in patients undergoing neoadjuvant HER2-based chemotherapy.26 Several in vitro preclinical studies have demonstrated promising results with chimeric antigen receptor (CAR) HER2-CAR NK in HER2-expressing tumors,27 as well as improved lysis of erbB2-expressing (HER2 gene), triple-negative breast cancer cell lines.28 In addition, in vitro studies with epidermal growth factor receptor targeting CAR NK cells plus oncolytic herpes simplex virus in a triple-negative cell line have shown promise.29

Several cytokines that normally stimulate NK cell activity including IL-2, IL-12, and IL-15 and TGF-β have been evaluated in the preclinical and clinical settings, and although several preclinical studies have been promising, clinical data have yet to pan out.23,30 Interleukin 12 has been evaluated in combination with trastuzumab (Herceptin) (NCT00004074, trial completed; NCT00028535, trial completed), but data have yet to be published. There is specific interest in targeting TGF-β given its immunosuppressive role within the breast cancer tumor microenvironment (TME), including its impact on NK function.31,32 Several clinical trials have evaluated donor NK cells plus IL-2 in advanced breast cancer, but there has been limited activity to date (NCT00376805, trial terminated early because of toxicity; NCT01105650, trial completed, no published results). Because HER2 is also expressed on other solid tumors including ovarian, esophageal, bladder cancer, and gastric cancers,33 autologous NK cells combined with trastuzumab in HER2-expressing solid tumors have been evaluated in the clinical setting and produced preliminary signs of efficacy.34 Another promising agent is DF1001, a small molecule that targets NK cells and T-cell activation signals in HER2-expressing tumors. DF1001 is being evaluated in HER2-expressing tumors in a phase I/II clinical trial (NCT04142711, ongoing clinical trial) as part of the Dragonfly Therapeutics TrNKT platform.

Pediatric Mesenchymal Tumors
A majority of the non–central nervous system, nonhematologic solid tumors in pediatrics are of mesenchymal origin, so tumors of epithelial origin are relatively rare in this age group. However, atypical solid tumors of neuroepithelial, neuroectodermal, embryonal, or undifferentiated origin (e.g., melanoma, neuroblastoma, primitive neuroectodermal tumors [PNETs], germ-cell tumors, Ewing sarcoma [EWS]) are relatively frequent. These tumors share epithelial-like features and frequently show sensitivity to NK cell recognition and lysis. Treatment for these pediatric tumors is typically multimodal, combining cytotoxic chemotherapy, radiation, and surgery. The adverse effects of these treatments frequently persist into adulthood with long-term negative health outcomes, so the addition of effective cell therapy holds the promise of maximizing targeted cytotoxicity while minimizing adverse effects, particularly for relapsed disease. Natural killer cells are an attractive treatment option for this group for several reasons.

Low MHC-I expression has been reported for many of these tumors (particularly neuroblastoma, EWS,35 and poorly differentiated rhabdomyosarcomas [RMSs]36,37) and is associated with high-risk patients and disease progression. Although this corresponds to escape from adaptive immune recognition, pediatric tumors with low MHC-I are an ideal target for NK cell adoptive therapies because these target cells cannot deliver an inhibitory signal through KIR or NKG2A and are therefore highly susceptible to NK cell lysis as defined in the “missing-self” hypothesis.38 The NKG2 family, CD16/FeRIII, DNAM-1, and natural cytotoxicity receptors NKp30, NKp44, and NKp46 are crucial receptors for NK cell–mediated targeting of low MHC-I tumors, and these receptors have been targeted in preclinical studies of pediatric solid tumors. NKp30 and NKp46 have specifically been implicated in NK cell–mediated cell lysis of neuroblastoma cell lines.39 Importantly, NK cells have been shown to eliminate metastases via NKp46.40

However, NK cells have been shown to be largely reduced or have impaired activity in many newly diagnosed oncology patients.32,41 In osteosarcoma, for example, NK cells show intact functionality and interferon γ production but low numbers,42 and early recovery of lymphocytes after chemotherapy is associated with improved survival.43 These findings suggest that NK cells are critical to survival in solid tumor patients and suggest that NK cell infusions may be a viable treatment option to restore number and function of endogenous NK cells.

Whereas autologous hematopoietic stem cell transplantation is commonly used in neuroblastoma, allogeneic hematopoietic stem cell transplantation has the added potential benefit of the graft-versus-tumor (GVT) effect. Specifically, haploidentical transplants offer a unique opportunity for intentional mismatch of donor NK cells (with respect to HLA licensing of inhibitory KIR) against HLA molecules present on the tumor, enhancing the GVT effect.44 As GVHD is T-cell mediated, NK cells present a viable treatment option that minimizes GVHD while maintaining GVT effect.45 Several studies utilizing manipulated haploidentical transplant have been performed in patients with relapsed solid tumors, including with desmoplastic small round cell tumor, neuroblastoma, RMS, EWS, and PNET. Survival in this heavily pretreated population was 6 to 14 months46,47 and demonstrated feasibility of NK cell–enriched haploidentical transplants, but also showed the need for further immunomodulation and refinement with combination trials such as those as outlined in Table 1.

As mentioned previously, the graft-versus-tumor effect of allogeneic NK cells may be maximized by selecting for KIR mismatch.51 Although the benefit of KIR-mismatched NK cells in leukemia is relatively well documented,52–56 more clinical and preclinical studies are needed to demonstrate the benefit of KIR mismatch in pediatric solid tumors. Delgado et al.57 found that osteosarcoma cell lines were most sensitive to allogeneic NK cell lysis when KIR receptor–ligand incompatibility was maximized. In addition, activating KIR gene content has been associated with increased NK potency against a variety of pediatric tumors including EWS, RMS, neuroblastoma, lymphoma, leukemia, and brain tumors.58 Preclinical models in vitro and in mouse models have consistently demonstrated the importance of IL-2, IL-15, and IL-21 for NK cell activation.59–61 We developed an NK cell expansion system utilizing membrane-bound IL21 that resolves some of the obstacles faced with NK cell clinical trials, enabling sufficient cell
| Clinical Trial No. | Phase | Title                                                                 | Sponsor Institution                                           | Status                        | Condition Treated                                                      |
|-------------------|-------|----------------------------------------------------------------------|--------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------|
| NCT00582816       | 1     | Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors | University of Wisconsin, Madison                             | Terminated (toxicity)         | Relapsed/refractory leukemia or solid tumors                           |
| NCT01875601       | 1     | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | National Cancer Institute                                     | Completed                     | Relapsed/refractory solid tumors                                      |
| NCT00640796       | 1     | Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors | St. Jude Children's Research Hospital                        | Completed                     | Relapsed/refractory hematologic malignancies, EWS family of tumors (ESFT) and RMS |
| NCT02130869       | 1     | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133\(^+\) Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | St. Jude Children's Research Hospital                        | Completed                     | Relapsed/refractory neuroblastoma, lymphoma, high-risk solid tumor    |
| NCT02100891       | 2     | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR) | Medical College of Wisconsin                                 | Active, not recruiting         | Relapsed/refractory neuroblastoma, EWS, RMS, osteosarcoma, central nervous system tumors |
| NCT02508038       | 1     | Alpha/Beta CD19\(^+\) Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | University of Wisconsin, Madison                             | Recruiting                    | Relapsed/refractory leukemia, lymphoma, neuroblastoma, EWS, RMS, osteosarcoma, PNET |
| NCT01576692       | 1     | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | St. Jude Children's Research Hospital                        | Completed                     | Relapsed/refractory neuroblastoma                                      |
| NCT03209869       | 1     | Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14-IL2 | University of Wisconsin, Madison                             | Suspended (COVID)             | Relapsed/refractory neuroblastoma and osteosarcoma                     |
| NCT00877110       | 1     | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | Memorial Sloan Kettering Cancer Center                     | Completed                     | Relapsed/refractory neuroblastoma                                      |
| NCT02650648       | 1     | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | Memorial Sloan Kettering Cancer Center                     | Active, not recruiting         | Relapsed/refractory neuroblastoma                                      |
| NCT02573896       | 1     | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | New Approaches to Neuroblastoma Therapy Consortium           | Recruiting                    | Relapsed/refractory neuroblastoma                                      |
| NCT00698009       | 1     | Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | MD Anderson Cancer Center                                    | Terminated (slow accrual)     | Relapsed/refractory neuroblastoma                                      |
| NCT03294954       | 1     | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2) | Texas Children's Hospital                                    | Recruiting                    | Relapsed/refractory neuroblastoma                                      |
| NCT01287104       | 1     | A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias | National Cancer Institute                                    | Completed                     | Relapsed/refractory leukemia or solid tumors                           |

Continued next page
TABLE 1. (Continued)

| Clinical Trial No. | Phase | Title | Condition Treated | Institution | Status | Sponsor Institution |
|-------------------|-------|-------|------------------|-------------|--------|---------------------|
| NCT03420963       | 1     | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | Relapsed/refractory solid tumors | Nationwide Children's Hospital | Recruiting | MD Anderson |
| NCT04211675       | 1 and 2 | A Phase 1-2 Study of E-Ciervo, Expanded Autologous NK Cells Infusions in Combination With Irinotecan, Temozolomide, and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma: The STING Trial | Relapsed/refractory neuroblastoma | St. Jude Children's Research Hospital | Active, not recruiting | Nationwide Children's Hospital |
| NCT01857934       | 2     | Therapy for Children With Advanced Stage Neuroblastoma | Newly diagnosed high-risk neuroblastoma | St. Jude Children's Research Hospital | Recruiting | MD Anderson |

numbers for adoptive transfer of multiple doses, functional activation/priming, and successful cryopreservation.52,63

Among pediatric tumors, neuroblastoma has been the most studied target for NK cell immunotherapy. GD2 is a ganglioside expressed throughout the central nervous system and is found on human neural stem cells, mesenchymal stem cells, peripheral nerve cells, and melanocytes, and expression is increased in many solid tumors, including neuroblastoma, osteosarcoma, soft tissue sarcomas, and desmoplastic small round cell tumor.64–66 Anti-GD2 monoclonal antibodies, including dinutuximab and naxitamab, kill tumor cells in an NK cell–dependent fashion by ADCC and NK cell–independent fashion by complement-mediated cytotoxicity. These antitumor effects are augmented by coadministration with cytokines such as granulocyte-macrophage colony-stimulating factor and IL-2.67 Combination therapy with NK cells may be a strategy to augment ADCC and is being explored in several clinical trials.

Combination therapy with NK cells and anti-GD2 antibodies has been used in several clinical trials for neuroblastoma. In a pilot study, NK cells derived from parents were administered with the Fc-modified anti-GD2 antibody hu14.18K322A after cycles 2, 4, and 6 of chemotherapy in 13 heavily treated patients with relapsed/refractory neuroblastoma. The overall response rate was 61.5% (4 complete responses, 1 very good partial response, and 3 partial responses), and 5 had a stable disease, with 77% overall survival at 1 year.68 A similar phase I trial combined the anti-GD2 antibody 3F8 with haploidentical NK cells administered after lymphodepleting chemotherapy in 35 patients.6 Improved event-free survival was seen in patients receiving more than 10^7 NK cells.69 These suggest that NK cells can be safely combined with anti-GD2 antibodies with preliminary evidence of antineuroblastoma effects, especially at higher NK cell doses. A clinical trial administering expanded autologous NK cells (to increase the cell dose) with dinutuximab (NCT02573896) and another delivering haploidentical NK cells along with an antibody-cytokine fusion protein (Hu14.18-IL-2) to increase in vivo NK cell proliferation are underway for pediatric patients with relapsed neuroblastoma (NCT03209869).

Clinical trials are underway administering NK cells (NCT02839954) or NK cell lines (NCT03656705 and NCT03383978) expressing CARs targeting solid tumor antigens on pediatric cancers, but the trials have so far been limited to adult participants, and results have not yet been reported.

Natural killer cells have been explored for treatment in osteosarcoma, both in human and in canine models.69 Canine osteosarcoma has long been used as a model for pediatric osteosarcoma, given the similar biology, response to therapy, and even size of the patients.70 Preliminary human in vitro studies demonstrated that NK cells lyse osteosarcoma cell lines in a manner dependent on NKG2D receptor-ligand interaction; this process also demonstrated effectiveness against multiple subpopulations of osteosarcoma cells, including those most responsible for recurrence.71 Autologous expanded NK cells were given via intralesional injection in dogs not undergoing amputation (standard of care), supplemented with intravenous IL-2 treatment and palliative radiation. Four dogs were killed for progressive disease, and 2 died of unrelated causes. Four dogs (40%) remained alive at 18 months.1,72 This use of such outbred comparative oncology models of NK cell immunotherapy is useful for translation into pediatric clinical trials.

In addition to neuroblastoma and osteosarcoma, EWS and RMS have shown in vitro susceptibility to NK cells. Ray et al.58 showed the importance of activating KIR content for enhanced NK cell cytolytic activity against pediatric cancer targets including RMS and ES. Natural killer cell function is also enhanced by cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Interleukin 15 is the most commonly studied cytokine for enhancing NK cell propagation, survival, and cytolytic function,60 and RMS,
EWS, and osteosarcoma cell lines are susceptible, particularly after IL-15, to allogeneic NK cells. Insulinlike growth factor receptor 1 is important for EWS development which can be targeted by antibodies that have activity against EWS, and targeting shows improved activity in combination therapy with NK cells.

Addressing the Solid Tumor Microenvironment

Tumors induce an environment that is favorable to tumor cell growth and resistant to immune responses, known as the TME. In the course of rapid tumor growth that outstrips vascular supply, the TME has progressively restricted access to both glucose and oxygen, creating a nutrient-poor and hypoxic environment. Malignant cells are able to survive and drive metastatic spread under glucose deprivation. In soft tissue sarcomas, hypoxia is closely linked to relapse, and the 5-year overall survival is approximately 50% in patients with high-risk disease. Hypoxia-inducible factors (HIFs) are the main transcriptional regulators in response to hypoxia, with an oxygen-regulated α subunit (HIF-1α or HIF-2α) that dimerizes with HIF-1β under hypoxia. Hypoxia-inducible factor 1α was previously described as a regulator of TGF-β-SMAD3 signaling in breast cancer patients. In addition to upregulating TGF-β, hypoxia is also closely linked to regulation of other immune-suppressive pathways such as indoleamine-2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO). Targeting these hypoxic conditions improves immune responses and reduces the risk of lung metastasis in experimental sarcoma models.

The TME can also induce metabolic reprogramming of the tumor-infiltrating immune cells themselves, in part due to their large energy consumption rate. Cellular metabolism is necessary to provide the energy needed for critical functions of antitumor activity and is necessary to maintain homeostasis such as redox balance. Transforming growth factor β is a potent immune suppressor of NK cell antitumor function and is an abundant cytokine present in the TME that regulates cell proliferation, carcinogenesis, and angiogenesis and is linked to chemotherapy and radiation resistance, in addition to immune suppression. Our group developed a unique platform expanding NK cells in the presence of TGF-β that induces epigenetic changes that result in TGF-β resistance through downregulation of SMAD3. Interestingly, the presence of TGF-β does not impact NK cell proliferation and paradoxically enhances production of the inflammatory cytokines interferon γ, tumor necrosis factor α, and granulocyte-macrophage colony-stimulating factor. We are developing pediatric and adult clinical trials of these TGF-β-resistant NK cells in neuroblastoma, brain tumors, sarcomas, melanoma, and breast carcinoma.

Together, IOD and TDO promote metabolism of tryptophan into kynurenine (Kyn) and kynurenic acid (KA); IOD and TDO are commonly upregulated in tumors, and the resulting Kyn/KA are highly inhibitory to antitumor immunity in several models. Kyn/KA exert their action on NK cells through binding to the aryl hydrocarbon receptor (AHR), resulting in immune suppression and tolerance. Activation of AHR pathway by these ligands can operate in the inhibition of chemical skin carcinogenesis. In addition, AHR pathway by these ligands can operate in the regulation of immune responses and reduces the risk of immune-suppressive pathways such as indoleamine-2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase (TDO).

REFERENCES

1. Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. JAMA Dermatol. 2015;151:976–981.
2. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol. 2019;80:303–317.
3. Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: contemporary approaches to diagnosis, treatment, and prevention. J Am Acad Dermatol. 2019;80:321–339.
4. Vineresky KA, Karagas MR, Christensen BC, et al. Skin cancer risk is modified by KIR/HLA interactions that influence the activation of natural killer immune cells. Cancer Res. 2016;76:370–376.
5. Youssefnejad F, Jowkar F, Barani S, et al. Killer cell immunoglobulin-like receptors (KIRs) genotype and haplotype analysis in Iranians with non-melanoma skin cancers. Iran Biomed J. 2019;23:330–337.
6. Garcia-de-la-Fuente MR, Santacana M, Verduguer J, et al. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma. Australas J Dermatol. 2020;61:e200–e207.
7. Sullivan TP, Deanujo T, Vineck V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003;29:1181–1186.
8. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78:237–247.
9. Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419–428.
10. Bibee K, Swartz A, Sridharan S, et al. Cutaneous squamous cell carcinoma in the organ transplant recipient. Oral Oncol. 2020;103:105462.
11. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305.
12. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
13. Ilyas M, Costello CM, Sharma A. Exploring the relationship between natural killer cells and cutaneous squamous cell carcinoma development. JAA Case Rep. 2017;3:364–366.
14. Carroll RR, Segundo DS, Hollowood K, et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol. 2010;21:713–722.
15. Pahl JH, Ruslan SE, Buddingh EP, et al. Anti-EGFR antibody cetuximab phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305.
16. Arianfar E, Shahgordi S, Memarian A. Natural killer cell defects in breast cancer. J Clin Oncol. 2019;37:329–338.
17. Bahari RM, Risland SE, Buddingh EP, et al. Anti-EGFR antibody cetuximab phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305.
18. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
19. Ilyas M, Costello CM, Sharma A. Exploring the relationship between natural killer cells and cutaneous squamous cell carcinoma development. JAA Case Rep. 2017;3:364–366.
20. Carroll RR, Segundo DS, Hollowood K, et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol. 2010;21:713–722.
21. Rahimi S, Bahn ES, Bahn ES, et al. Natural killer cell defects in breast cancer. J Clin Oncol. 2019;37:329–338.
22. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
23. Arianfar E, Shahgordi S, Memarian A. Natural killer cell defects in breast cancer. J Clin Oncol. 2019;37:329–338.
24. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
25. Arianfar E, Shahgordi S, Memarian A. Natural killer cell defects in breast cancer. J Clin Oncol. 2019;37:329–338.
26. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
27. Arianfar E, Shahgordi S, Memarian A. Natural killer cell defects in breast cancer. J Clin Oncol. 2019;37:329–338.
28. Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol. 2006;118:526–528.
24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.

25. Peppi M, Derer S, Lobhe S, et al. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytototoxicity. Oncotarget. 2015;6:23075–23088.

26. Muraro E, De Zorti M, Miozo G, et al. KIR-HLA functional repertoire influences trastuzumab efficiency in patients with HER2-positive breast cancer. Front Immunol. 2022;12:791958.

27. Schönfeld K, Sahn C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23:330–338.

28. Liu H, Yang B, Sun T, et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells. Oncol Rep. 2015;33:95–102.

29. Uherek C, Tonin T, Uherek B, et al. Retargeting of natural killer-cell cyto- lytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100:1265–1273.

30. Chen X, Han J, Chu J, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7:27764–27777.

31. Knudson KM, Hicks KC, Alter S, et al. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-1 l therapy. J Immunother Cancer. 2019;7:82.

32. Leong JW, Chase JM, Romree R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20:463–473.

33. Slattery K, Woods E, Zaiatn-Bittencourt V, et al. TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer. J Immunother Cancer. 2021;9:e002044.

34. Foltz JA, Moseman JE, Thakkar A, et al. TGFβ imprinting during activation promotes natural killer cell cytokine hypersecretion. Cancers (Basel). 2018;10:423.

35. Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in di- rectly targeted cancer cells is associated with reduced response to immune checkpoint blockade. Proc Natl Acad Sci U S A. 2019;116:23666–23675.

36. Lee SC, Shimasaki N, Lim JSJ, et al. Phase I trial of expanded, activated human cytokine-induced memory-like natural killer cells. EBioMedicine. 2020;59:102975.

37. Ciurea SO, Kongtimg P, Soobbing D, et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022;36:155–164.

38. Meazza R, Falco M, Loiacono F, et al. Phenotypic and functional characterization of NK cells in patients with anti-β2-Fc and B-cell depleted haplo-HSCT due to pediatric patients with acute leukemia. Cancers (Basel). 2020;12:2187.

39. Nguyen R, Wu H, Bounds S, et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer. 2019;7:81.

40. Ray AK, Somanchi SS, Dastgheyb N, et al. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019;66:e27783.

41. Bartosak N, Wolter S, et al. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatr Blood Cancer. 2019;66:e27783.

42. Buddingh EP, Ruslan MW, Ruslan SE, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother. 2011;60:575–586.

43. Markiewicz K, Zerez T, Kozar A, et al. Evaluation of selected parameters of specific immunity in children with osteosarcoma at various stages of antitumour treatment [in Polish]. Der Period Med. 2014;18:155–168.

44. Moore C, Edlin D, Levy A, et al. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 2010;55:1096–1102.

45. Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34:1433–1443.

46. Olson JA, Zeiser R, Beilhack A, et al. Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. J Immunol. 2009;183:3219–3228.

47. Locatelli F, Pende D, Falco M, et al. NK cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia. Trends Immunol. 2018;39:577–590.

48. Lang P, Pfeiffer M, Müller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006;218:321–326.

49. Llosa NJ, Cooke KR, Chen AR, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–2136.

50. Llosa NJ, Cooke KR, Chen AR, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–2136.

51. Llosa NJ, Cooke KR, Chen AR, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–2136.

52. Llosa NJ, Cooke KR, Chen AR, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–2136.

53. Llosa NJ, Cooke KR, Chen AR, et al. Reduced-intensity haploidentical bone marrow transplantation with post-transplant cyclophosphamide for solid tumors in pediatric and young adult patients. Biol Blood Marrow Transplant. 2017;23:2127–2136.
68. Kisseberth WC, Lee DA. Adoptive natural killer cell immunotherapy for canine osteosarcoma. *Front Vet Sci*. 2021;8:672361.

69. Al-Khan AA, Gunn HJ, Day MJ, et al. Immunohistochemical validation of spontaneously arising canine osteosarcoma as a model for human osteosarcoma. *J Comp Pathol*. 2017;157:256–265.

70. Fernández L, Valentin J, Zalacain M, et al. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. *Cancer Lett*. 2015;365:54–63.

71. Canter RJ, Grossenbacher SK, Foltz JA, et al. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. *J Immunother Cancer*. 2017;5:98.

72. Judge SJ, Yanagisawa M, Sturgill IR, et al. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. *PLoS One*. 2020;15:e0224775.

73. Atzpodien J, Gulati SC, Shimazu C, et al. Ewing’s sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing. *Oncology*. 1998;45:437–445.

74. Verhoeven DH, de Hooge AS, Mooiman EC, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. *Mol Immunol*. 2008;45:3917–3925.

75. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. *Cancer Lett*. 2015;365:54–63.

76. Huang HJ, Angelo LS, Rodon J, et al. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing sarcoma: improved knowledge with unchanged survival over time.

77. Jamitzky S, Krueger AC, Janneschuetz S, et al. Hypoxia-driven selection of the metastatic phenotype. *Cancer Metastasis Rev*. 2019;50:924–940.

78. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. *Cancer Metastasis Rev*. 2019;50:924–940.